Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Smokingjoe. hope you got in at a good price?
nasdaq +30% now...
Very exciting times ahead.
They know how significant the fast track is -
"In October 2019, the U.S. Food and Drug Administration ("FDA") granted Fast Track designation to navicixizumab and has agreed in principle on the design of a study that could potentially support accelerated approval for navicixizumab in a heavily pretreated, platinum-resistant ovarian cancer patient population."
GLA
US 35% up
America picking up if they were smart they would buy here
Should get a Tr1 soon
https://www.lse.co.uk/rns/MPH/notification-of-holdings-in-company-pkxwdscviz3dgz7.html
Schoders
those two I think were Woodfords holdings
Schroders took over the Woodford's fund. It was another institution, Invesco, that was starting to sell a large holding recently.
Yes it transferred to Link
The RNS that said Woodford was out. Did the holding not transfer across to Link Fund Solutions? I'm having a look now. Seen this before where Wouldford have sold out but the holding has been transferred over to Link Fund.
draft, I was holding since December and really hoped that I could find some profits here, I don't want this to be another long term one.. f*** MM's games! GLA
I think there are 2 big issues. The high cashburn - it burnt through £27.63 million in six months and the company said in the last accounts it will have to raise funds soon. Also Invesco was selling down its holding, see the recent holdings RNS. It still owns around 20% of the company and are likely to sell into today's liquidity.
took a loss. didn't really know the story here and blindly went in. big error.
Can buy £10,000 worth at 40p.
Many people have probably bought in on the spike without realising this is a Woodford share.
Just dropped massively down to 37.5p.
Hopefully it's not another pump and dump.. SP should be backed by the RNS.. somehow still melts..
should see some fireworks. lots of trades on Nasdaq
Getting quoted 45p to buy decent amounts now
selling for losses. crazy, cant hold for more than 1 hour
Can see this moving north again today spread is tight.
The FDA has granted Fast Track designation to navicixizumab for the treatment of high grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least 3 prior therapies and/or prior bevacizumab. Following a Type B End of Phase 1 meeting with the FDA held in July 2019, the FDA agreed in principle on an outline for a Phase 2 clinical trial that could potentially support accelerated approval of navicixizumab in this ovarian cancer patient population.
Vwap over 43p, excellent entry price here
I read today's RNS then read the accounts. The amount this deal will bring in is very small compared to the cashburn so the company will still need to raise funds. The milestone payments depend on the drug being licenced which is will take years and there is obviously the risk of failing phase 2 and 3 trials.
In addition to the payments this massively derisks this and will make it attractive for the other IIs